Jump to content

BMND07

From Wikipedia, the free encyclopedia
BMND07
Combination of
DimethyltryptamineSerotonin receptor agonist Serotonergic psychedelic; Hallucinogen
5-MeO-DMTSerotonin receptor agonist Serotonergic psychedelic; Hallucinogen
UndisclosedUndisclosed
Clinical data
Other namesBMND-07

BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders.[1][2][3][4] It is being developed by Biomind Labs.[1][2] As of March 2022, it is in phase 1 clinical trials.[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c "BMND 07". AdisInsight. 16 March 2022. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on BMND-07 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ^ "Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07". BioSpace. 3 March 2022. Retrieved 16 February 2025. Biomind Labs' BMND07 drug candidate, a novel DMT combination drug, [...]
  4. ^ "Biomind Labs Provides Corporate Update". Business Wire. 27 September 2023. Retrieved 16 February 2025. BMND07: 5-methoxy-DMT ("5-MeO-DMT") free base organic synthesis
[edit]